Powder: -20°C for 3 years | In solvent: -80°C for 1 year
FR 180204 是一种 ATP 竞争性的选择性ERK 抑制剂,对ERK1和ERK2的Ki 值分别为 0.31 μM 和 0.14 μM,IC50值分别为0.51 μM 和0.33 μM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 253 | 现货 | ||
2 mg | ¥ 367 | 现货 | ||
5 mg | ¥ 595 | 现货 | ||
10 mg | ¥ 1,080 | 现货 | ||
25 mg | ¥ 1,960 | 现货 | ||
50 mg | ¥ 3,730 | 现货 | ||
100 mg | ¥ 5,380 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 687 | 现货 |
产品描述 | FR 180204 is a potent and selective ATP-competitive inhibitor of ERK1 and ERK2. |
靶点活性 | ERK2:0.14 μM(Ki), ERK1:0.31 μM(Ki) |
体外活性 | 在登革病毒(DENV)感染的小鼠模型中,FR180204限制肝细胞凋亡,减少DENV诱导的肝损伤,并改善临床参数.在胶原诱导的关节炎小鼠中,FR180204(100 mg/kg,i.p.,b.i.d.)显著降低症状和体重减轻的严重程度 |
体内活性 | FR 180204抑制自发性间皮瘤细胞生长。在AP-1转染的细胞中,FR180204剂量依赖性地抑制AP-1反式激活,IC50为3.1 μM。 |
激酶实验 | ERK assay: Nunc-Immuno MaxiSorp plates are coated with 20 μg/ml MBP solution in phosphate-buffered saline (PBS). After washing with PBS containing 0.05% Tween 20 (T-PBS), blocking buffer (T-PBS containing 3% BSA) is added to each well and the plates are incubated for 10 min at room temperature. After washing with T-PBS, chemical compounds, ATP and recombinant ERK2 diluted in assay dilution buffer (20 mM Mops, pH 7.2, 25 mM β-glycerol phosphate, 5 mM EGTA, 1 mM sodium orthovanadate, 1 mM dithiothreitol, and 50 μg/ml BSA) and are added to each well. Vehicle groups (containing 0.1% DMSO) and kinase-withdrawal groups are used for the control and basal determinations. After incubation for 1 h at room temperature, plates are washed twice with T-PBS. Anti-phospho MBP antibody (0.2 μg/ml) is added to each well, and the plates are incubated for 1 h at room temperature. After washing, anti-mouse HRP-conjugated polyclonal antibodies are added and the plates were incubated for 30 min. SuperSignal chemiluminescent substrate is used for the measurement of HRP activity according to the manufacturer's instructions. Prism 4.0 software is used for the Lineweaver–Burk plot analysis, IC50 and Ki determinations. |
细胞实验 | Cell viability is assayed by the method using MTT. MTT-reactive cells are quantified at an absorbance of 570 nm using a micro-plate reader. (Only for Reference) |
别名 | FR180204 |
分子量 | 327.34 |
分子式 | C18H13N7 |
CAS No. | 865362-74-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 32.7 mg/mL (100 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.0549 mL | 15.2746 mL | 30.5493 mL | 76.3732 mL |
5 mM | 0.611 mL | 3.0549 mL | 6.1099 mL | 15.2746 mL | |
10 mM | 0.3055 mL | 1.5275 mL | 3.0549 mL | 7.6373 mL | |
20 mM | 0.1527 mL | 0.7637 mL | 1.5275 mL | 3.8187 mL | |
50 mM | 0.0611 mL | 0.3055 mL | 0.611 mL | 1.5275 mL | |
100 mM | 0.0305 mL | 0.1527 mL | 0.3055 mL | 0.7637 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
FR 180204 865362-74-9 Apoptosis MAPK ERK Extracellular signal regulated kinases FR-180204 FR180204 Inhibitor inhibit inhibitor